Celltrion, Inc. (068270.KS)
KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
At close: 03:30PM KST
| Previous Close | 177,400.00 |
| Open | 177,500.00 |
| Bid | 176,800.00 x 0 |
| Ask | 177,000.00 x 0 |
| Day's Range | 176,300.00 - 178,800.00 |
| 52 Week Range | 131,000.00 - 241,000.00 |
| Volume | |
| Avg. Volume | 629,441 |
| Market Cap | 36.53T |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | 500.00 (0.28%) |
| Ex-Dividend Date | Dec 27, 2023 |
| 1y Target Est | 229,929.00 |
- Thomson Reuters StreetEvents
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
PR NewswireZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.
Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1] ZYMFENTRA is the first and only subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
- PR Newswire
Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)
Celltrion USA today announced that the company has submitted a Biologics License Application (BLA) for CT-P39, an interchangeable biosimilar candidate to XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA).[1]
© 2024 Yahoo. All rights reserved.